Supplementary	Table S1. Single-cell	data statistics for	[.] each human	cancer typ	pe
----------------------	-----------------------	---------------------	-------------------------	------------	----

Cancer type	Abbreviation	Protocols	# Samples	# Cell count in	# Average UMI count in	# Average gene	Literatures
				each sample	each cell	count in each cell	
Merkel Cell Carcinoma	MCC	10X Genomics	4	2,401 – 5,477	3,667 – 6,460	1,496 – 2,326	https://pubmed.ncbi.nlm.nih.gov/30827681
Lung Adenocarcinoma	LUAD	10X Genomics	21	635 – 4,832	2,204 – 15,218	789 – 2,665	https://pubmed.ncbi.nlm.nih.gov/32042191
							https://pubmed.ncbi.nlm.nih.gov/29988129
Lung Squamous Cell Carcinoma	LUSC	10X Genomics	7	105 – 1,586	3,795 – 5,585	973 – 1,285	https://pubmed.ncbi.nlm.nih.gov/29988129
Non-small Cell Lung Cancer	NSCLC	10X Genomics	7	2,863 - 13,382	2,688 – 8,867	904 – 2,263	https://pubmed.ncbi.nlm.nih.gov/29988129
Triple Negative Breast Cancer	TNBC	10X Genomics	6	333 – 1,964	5,299 – 15,768	1,394 – 3,879	https://pubmed.ncbi.nlm.nih.gov/33462507
Glioblastoma	GBM	Drop-seq, 10X	49	272 – 28,764	558 – 927,701	358 – 3,253	https://pubmed.ncbi.nlm.nih.gov/31883794
		Genomics,					https://pubmed.ncbi.nlm.nih.gov/32004492
		Smart-seq2,					https://pubmed.ncbi.nlm.nih.gov/29091775
		Microwell					https://pubmed.ncbi.nlm.nih.gov/30041684
							https://pubmed.ncbi.nlm.nih.gov/33975634/
Anaplastic Astrocytoma	AA	Microwell	1	6,960	973	647	https://pubmed.ncbi.nlm.nih.gov/30041684
Stomach Adenocarcinoma	STAD	10X Genomics	1	1,467	9,763	2,152	https://pubmed.ncbi.nlm.nih.gov/31067475
Colorectal Cancer	CRC	10X Genomics	16	322 – 3,371	2,412 – 16,633	926 – 2,958	https://pubmed.ncbi.nlm.nih.gov/32451460
Neuroendocrine Tumor	NBL	10X Genomics	2	855 – 2,518	1,486 – 3,114	819 – 1,406	https://pubmed.ncbi.nlm.nih.gov/32054662
Basal Cell Carcinoma	BCC	10X Genomics	5	112 - 253	3,572 – 11,569	1,350 – 2,512	https://pubmed.ncbi.nlm.nih.gov/31359002
Ovarian Carcinoma	OV	10X Genomics	4	3,439 – 5,846	6,584 – 10,348	2,459 – 3,135	https://pubmed.ncbi.nlm.nih.gov/32054838
Mixed-phenotype Acute	MPAL	10X Genomics	10	195 – 5,643	2,009 – 4,151	1,035 – 1,906	https://pubmed.ncbi.nlm.nih.gov/31792411
Leukemia							
Muscle-invasive Urothelial	MIUBC	10X Genomics	1	1,809	3,690	2,148	https://pubmed.ncbi.nlm.nih.gov/32460812
Bladder Cancer							
Endometrial Carcinoma	UCEC	10X Genomics	6	329 – 1,436	14,187 – 17,930	3,050 – 3,971	https://pubmed.ncbi.nlm.nih.gov/32686114
Hepatocellular Cancer	нсс	10X Genomics	2	2,888 - 6,582	2,965 – 3,116	1,001 – 1,085	https://pubmed.ncbi.nlm.nih.gov/30068984
Anaplastic Thyroid Cancer	ATC	10X Genomics	5	1,174 – 5,861	6,035 – 14,794	1,824 – 3,098	https://pubmed.ncbi.nlm.nih.gov/33462507
Pancreatic Ductal	PDAC	10X Genomics	24	1,079 – 8,202	2,819 – 8,093	1,177 – 2,502	https://pubmed.ncbi.nlm.nih.gov/31273297
Adenocarcinoma							
Breast Ductal Carcinoma in Situ	DCIS	10X Genomics	1	1,114	14,234	3,428	https://pubmed.ncbi.nlm.nih.gov/33462507
Acute Myeloid Leukemia	AML	Seq-Well	36	285 – 5,996	687 – 4,651	389 – 1,751	https://pubmed.ncbi.nlm.nih.gov/30827681



Supplementary Figure S1. The average expression pattern of immune checkpoint molecules across 20 human cancer types. For each cancer type, only one sample with relatively larger sample size and higher cell diversities was selected, and the average expression values were calculated for each specific cell type and marked with different colors (legend on the right panel). The normalized expressions range from 0 (beige) to 3 (red).